Impact of Nesiritide Infusion for Decompensated Heart Failure in the Emergency Department

PHASE4CompletedINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

December 31, 2003

Study Completion Date

April 30, 2005

Conditions
Heart Failure, CongestiveCardiomyopathy
Interventions
DRUG

recombinant B-type, natriuretic peptide

The intravenous infusion of nesiritide consisted of a bolus dose of 2mcg/kg followed by the infusion rate of 0.01 mcg/kg/min for up to eight hours. The nesiritide was mixed in 250 ml of 0.9% normal saline solution.

DRUG

placebo

The intravenous infusion of placebo consisted of a bolus dose of 2mcg/kg followed by the infusion rate of 0.01 mcg/kg/min for up to eight hours. The placebo was mixed in 250 ml of 0.9% normal saline solution.

Trial Locations (1)

75390

Parkland Hospital, Dallas

All Listed Sponsors
collaborator

Scios, Inc.

INDUSTRY

lead

University of Texas Southwestern Medical Center

OTHER

NCT00559338 - Impact of Nesiritide Infusion for Decompensated Heart Failure in the Emergency Department | Biotech Hunter | Biotech Hunter